FTC Clears Barr’s Acquisition Of Pliva Based On Divestiture Of Generic Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr must divest three generic products – trazodone, triamterene/HCTZ and nimodipine – to Apotex and Banner.
You may also be interested in...
Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products
The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.
Barr Shifts Roles At The Top, Splits Up Senior Management Duties
Restructure frees CEO Downey of responsibilities he assumed when Bisaro jumped to Watson in August.
Barr Shifts Roles At The Top, Splits Up Senior Management Duties
Restructure frees CEO Downey of responsibilities he assumed when Bisaro jumped to Watson in August.